Literature DB >> 23490233

Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.

Cindy Parks Thomas1, Deborah W Garnick, Constance M Horgan, Kay Miller, Alex H S Harris, Melissa M Rosen.   

Abstract

This paper presents the rationale and feasibility of standardized performance measures for use of pharmacotherapy in the treatment of substance use disorders (SUD), an evidence-based practice and critical component of treatment that is often underused. These measures have been developed and specified by the Washington Circle, to measure treatment of alcohol and opioid dependence with FDA-approved prescription medications for use in office-based general health and addiction specialty care. Measures were pilot tested in private health plans, the Veterans Health Administration (VHA), and Medicaid. Testing revealed that use of standardized measures using administrative data for overall use and initiation of SUD pharmacotherapy is feasible and practical. Prevalence of diagnoses and use of pharmacotherapy vary widely across health systems. Pharmacotherapy is generally used in a limited portion of those for whom it might be indicated. An important methodological point is that results are sensitive to specifications, so that standardization is critical to measuring performance across systems.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23490233      PMCID: PMC3954716          DOI: 10.1016/j.jsat.2013.01.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  51 in total

1.  On-site provision of substance abuse treatment services at community health centers.

Authors:  Deborah Gurewich; Jenna T Sirkin; Donald S Shepard
Journal:  J Subst Abuse Treat       Date:  2011-11-23

Review 2.  Defining and measuring quality of care: a perspective from US researchers.

Authors:  R H Brook; E A McGlynn; P G Shekelle
Journal:  Int J Qual Health Care       Date:  2000-08       Impact factor: 2.038

3.  Advancing performance measures for use of medications in substance abuse treatment.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Frank McCorry; Amanda Gmyrek; Mady Chalk; David R Gastfriend; Suzanne Gelber Rinaldo; Joann Albright; Victor A Capoccia; Alex H S Harris; Henrick J Harwood; Pamela Greenberg; Tami L Mark; Huong Un; Marla Oros; Mark Stringer; James Thatcher
Journal:  J Subst Abuse Treat       Date:  2010-10-08

4.  From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Authors:  Walter Ling; Petra Jacobs; Maureen Hillhouse; Albert Hasson; Christie Thomas; Thomas Freese; Steven Sparenborg; Dennis McCarty; Roger Weiss; Andrew Saxon; Allan Cohen; Michele Straus; Gregory Brigham; David Liu; Paul McLaughlin; Betty Tai
Journal:  J Subst Abuse Treat       Date:  2010-06

Review 5.  Pharmacotherapy of adolescent substance use disorders: a review of the literature.

Authors:  James G Waxmonsky; Timothy E Wilens
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-10       Impact factor: 2.576

6.  Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels.

Authors:  S F Jencks; T Cuerdon; D R Burwen; B Fleming; P M Houck; A E Kussmaul; D S Nilasena; D L Ordin; D R Arday
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

Review 7.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

8.  Measuring health care performance now, not tomorrow: essential steps to support effective health reform.

Authors:  Joachim Roski; Mark McClellan
Journal:  Health Aff (Millwood)       Date:  2011-04       Impact factor: 6.301

9.  Prescribing methadone for pain management in end-of-life care.

Authors:  John F Manfredonia
Journal:  J Am Osteopath Assoc       Date:  2005-03

10.  Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.

Authors:  Gary A Zarkin; Jeremy W Bray; Arnie Aldridge; Debanjali Mitra; Michael J Mills; David J Couper; Ron A Cisler
Journal:  Arch Gen Psychiatry       Date:  2008-10
View more
  16 in total

Review 1.  The Affordable Care Act: an opportunity for improving care for substance use disorders?

Authors:  Katherine E Watkins; Carrie M Farmer; David De Vries; Kimberly A Hepner
Journal:  Psychiatr Serv       Date:  2014-12-01       Impact factor: 3.084

2.  Effects of Global Payment and Accountable Care on Medication Treatment for Alcohol and Opioid Use Disorders.

Authors:  Julie M Donohue; Colleen L Barry; Elizabeth A Stuart; Shelly F Greenfield; Zirui Song; Michael E Chernew; Haiden A Huskamp
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

3.  Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders.

Authors:  Benjamin R Nordstrom; Elizabeth C Saunders; Bethany McLeman; Andrea Meier; Haiyi Xie; Chantal Lambert-Harris; Beth Tanzman; John Brooklyn; Gregory King; Nels Kloster; Clifton Frederick Lord; William Roberts; Mark P McGovern
Journal:  J Addict Med       Date:  2016 Mar-Apr       Impact factor: 3.702

4.  The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care.

Authors:  Tae Woo Park; Jeffrey H Samet; Debbie M Cheng; Michael R Winter; Theresa W Kim; Anna Fitzgerald; Richard Saitz
Journal:  J Subst Abuse Treat       Date:  2014-12-02

Review 5.  Preclinical Medication Development: New Targets and New Drugs.

Authors:  Chelsea R Kasten; Stephen L Boehm
Journal:  Alcohol Clin Exp Res       Date:  2016-05-14       Impact factor: 3.455

6.  Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.

Authors:  David Hui; Zoe M Weinstein; Debbie M Cheng; Emily Quinn; Hyunjoong Kim; Colleen Labelle; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2017-05-16

7.  Access to Addiction Pharmacotherapy in Private Health Plans.

Authors:  Sharon Reif; Constance M Horgan; Dominic Hodgkin; Ann-Marie Matteucci; Timothy B Creedon; Maureen T Stewart
Journal:  J Subst Abuse Treat       Date:  2016-03-14

Review 8.  Developing an opioid use disorder treatment cascade: A review of quality measures.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Harold A Pincus; Kimberly A Johnson; Aimee N Campbell; Remien H Remien; Stephen Crystal; Peter D Friedmann; Frances R Levin; Mark Olfson
Journal:  J Subst Abuse Treat       Date:  2018-06-02

9.  Design of CLARO (Collaboration Leading to Addiction Treatment and Recovery from other Stresses): A randomized trial of collaborative care for opioid use disorder and co-occurring depression and/or posttraumatic stress disorder.

Authors:  Lisa S Meredith; Miriam S Komaromy; Matthew Cefalu; Cristina Murray-Krezan; Kimberly Page; Karen Chan Osilla; Alex R Dopp; Isabel Leamon; Lina Tarhuni; Grace Hindmarch; Vanessa Jacobsohn; Katherine E Watkins
Journal:  Contemp Clin Trials       Date:  2021-03-10       Impact factor: 2.226

10.  Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.

Authors:  Kimberly Johnson; Holly Hills; Jifeng Ma; C Hendricks Brown; Mark McGovern
Journal:  Am J Drug Alcohol Abuse       Date:  2020-10-15       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.